https://www.selleckchem.com/pr....oducts/triiodothyron
Monoclonal antibodies targeting the programmed-death 1 (PD-1) immune checkpoint or its ligand PD-L1 have significantly improved the treatment of cancers but more efficient drugs and combinations are still needed to increase the therapeutic efficacy. As the oxidative state of the immune microenvironment plays a critical role in the antitumor immune response, it is important to evaluate the impact of molecules and drugs used for oxidative stress control on PD-L1 expression and functions. Here we have reviewed the functional relat
Like
Comment
Share
